A phase II clinical study of the safety and efficacy of toripalimab in combination with anilotinib for the treatment of recurrent glioblastoma
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 17 Jan 2025 New trial record